These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 37018002)

  • 1. Significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer.
    Nierengarten MB
    Cancer; 2024 Jul; 130(13):2245. PubMed ID: 38849650
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer.
    Sidaway P
    Nat Rev Clin Oncol; 2024 Jun; 21(6):402. PubMed ID: 38565936
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer].
    Raynaud C; Rodrigues M
    Bull Cancer; 2024 May; 111(5):433-434. PubMed ID: 38493028
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
    Makker V; Colombo N; Casado Herráez A; Monk BJ; Mackay H; Santin AD; Miller DS; Moore RG; Baron-Hay S; Ray-Coquard I; Ushijima K; Yonemori K; Kim YM; Guerra Alia EM; Sanli UA; Bird S; Orlowski R; McKenzie J; Okpara C; Barresi G; Lorusso D
    J Clin Oncol; 2023 Jun; 41(16):2904-2910. PubMed ID: 37058687
    [No Abstract]   [Full Text] [Related]  

  • 5. Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer.
    Romero D
    Nat Rev Clin Oncol; 2023 Jun; 20(6):353. PubMed ID: 37024681
    [No Abstract]   [Full Text] [Related]  

  • 6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
    Disis ML; Adams SF; Bajpai J; Butler MO; Curiel T; Dodt SA; Doherty L; Emens LA; Friedman CF; Gatti-Mays M; Geller MA; Jazaeri A; John VS; Kurnit KC; Liao JB; Mahdi H; Mills A; Zsiros E; Odunsi K
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
    Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
    Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives.
    Oaknin A; León-Castillo A; Lorusso D
    Curr Opin Oncol; 2020 Sep; 32(5):471-480. PubMed ID: 32740093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab Immunotherapy Improved Endometrial Cancer Survival.
    Harris E
    JAMA; 2023 Apr; 329(16):1341. PubMed ID: 37018002
    [No Abstract]   [Full Text] [Related]  

  • 10. Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
    Nierengarten MB
    Cancer; 2024 Jul; 130(13):2246. PubMed ID: 38849630
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Dilley SE; Smith HJ; Straughn JM
    Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
    Garcia C; Ring KL
    Curr Treat Options Oncol; 2018 Nov; 19(12):70. PubMed ID: 30397772
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.